Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | LGALS3 | P17931 | 5/20 | 0.41 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.36 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.34 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.34 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.34 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.33 |
| ▸ | CD69 | Q07108 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7154489 | 0.87 | LGALS3 (0.44) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL7155174 | 0.87 | LGALS3 (0.44) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL25043094 | 0.87 | MAPK1 (0.56) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL13491439 | 0.87 | MAPK1 (0.56) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL7591374 | 0.87 | MAPK1 (0.56) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL13308281 | 0.87 | MAPK1 (0.56) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL18391246 | 0.86 | MAPK1 (0.49) | MAPK1LGALS3ALDH1A1THRBKMT2A | |
| SCHEMBL26229737 | 0.86 | MAPK1 (0.49) | MAPK1LGALS3ALDH1A1THRBKMT2A | |
| SCHEMBL13240509 | 0.86 | MAPK1 (0.49) | MAPK1LGALS3ALDH1A1THRBKMT2A | |
| SCHEMBL4314010 | 0.86 | MAPK1 (0.49) | MAPK1LGALS3ALDH1A1THRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9933432-B2 | Multi-dimensional chromatographic methods for separating N-glycans | MOMENTA PHARMACEUTICALS, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170212129-A1 | MULTI-DIMENSIONAL CHROMATOGRAPHIC METHODS FOR SEPARATING N-GLYCANS | MOMENTA PHARMACEUTICALS, INC. | 2017-07-27 | — | — | US | disclosed |
| US-20160356783-A1 | MULTI-DIMENSIONAL CHROMATOGRAPHIC METHODS FOR SEPARATING N-GLYCANS | MOMENTA PHARMACEUTICALS, INC. | 2016-12-08 | — | — | US | disclosed |
| US-9448147-B2 | Multi-dimensional chromatographic methods for separating N-glycans | MOMENTA PHARMACEUTICALS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-8703498-B2 | Multi-dimensional chromatographic methods for separating N-glycans | MOMENTA PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20140065716-A1 | MULTI-DIMENSIONAL CHROMATOGRAPHIC METHODS FOR SEPARATING N-GLYCANS | MOMENTA PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20130029365-A1 | MULTI-DIMENSIONAL CHROMATOGRAPHIC METHODS FOR SEPARATING N-GLYCANS | MOMENTA PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8304250-B2 | Multi-dimensional chromatographic methods for separating N-glycans | MOMENTA PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20110213137-A1 | ISOTOPICALLY-LABELED GLYCANS | MOMENTA PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20100151584-A1 | MULTI-DIMENSIONAL CHROMATOGRAPHIC METHODS FOR SEPARATING N-GLYCANS | MOMENTA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213137-A1 | ISOTOPICALLY-LABELED GLYCANS | FUT5, FUT6, ST3GAL3 | MAPK1 4093/4885LGALS3 51/4885LGALS8 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.